CANCER BIOLOGY & THERAPY

简称 CANCER BIOL THER ·UNITED STATES ·出版周期 Monthly ·年均收录 142 篇

4.6

最新影响因子

1.40%

自引率

约50%

投稿难度

平均2.3月

审稿周期

期刊简介

CANCER BIOLOGY & THERAPY是一本专注于癌症生物学与治疗研究的国际期刊，ISSN号为1538-4047，由美国出版商Taylor & Francis集团出版，出版地为美国，出版周期为月刊。该期刊的影响因子根据年份有所不同，近年保持在3-4左右，属于SCI收录期刊，但并非完全开放获取（OA），在中科院分区中通常位于医学或生物学的3区或4区。杂志的发文特点涵盖癌症的基础与临床研究，包括肿瘤发生机制、分子靶点、治疗策略及药物开发等领域，尤其关注转化医学研究。其质量在癌症领域具有一定认可度，但影响因子相对中等，投稿时需注意审稿周期和竞争程度，同时需警惕个别年份的自引率风险。总体而言，该期刊适合发表癌症相关的中高水平研究，但需结合自身研究方向和投稿需求综合评估。

影响因子趋势

近期发表

Synchronizing immunity and angiogenesis in lung adenocarcinoma: bridging biological synergy and clinical translation 2026-09-08

Thioredoxin reductase-1 facilitates cellular plasticity and stemness mediated by TGF-β1 in non-small cell lung cancer 2026-09-08

DNA-PKcs and PARP1 at the interface between DNA damage responses and cGAS–STING signaling: context-dependent roles and therapeutic implications 2026-09-09

The molecular mechanisms of platelets in tumor invasion and metastasis: a controversial role 2026-08-11

DNA polymerase theta (Polθ): a novel candidate for targeted cancer therapy 2026-07-29

Molecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics 2026-07-29

Stress-specific 14-3-3–client modules in digestive cancers: an evidence-graded review of adaptive survival and therapy resistance 2026-07-27

Targeting molecular and genetic pathways driving tumorigenesis for precision therapy in colorectal cancer 2026-07-26

Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin 2026-07-20

A preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification 2026-07-14